Package Leaflet: Information for the Patient
Aerinaze 2.5mg/120mg Modified Release Tablets
desloratadine/pseudoephedrine sulfate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
|
Contents of the Package Leaflet
What is Aerinaze
Aerinaze tablets contain a combination of two active substances, desloratadine, which is an antihistamine, and pseudoephedrine sulfate, which is a decongestant.
How Aerinaze works
Antihistamines help to reduce allergic symptoms by preventing the effects of a substance called histamine, which is produced in the body. Decongestants help to relieve nasal congestion (blockage/congestion).
When to take Aerinaze
Aerinaze tablets relieve the symptoms associated with seasonal allergic rhinitis (hay fever) such as sneezing, runny or itchy nose, itchy or watery eyes, when accompanied by nasal congestion in adults and adolescents over 12 years of age.
Do not take Aerinaze
Warnings and precautions
Certain conditions may make you unusually sensitive to the decongestant pseudoephedrine sulfate contained in this medicine. Consult your doctor, pharmacist, or nurse before starting to take Aerinaze:
Additionally, if you experience or are diagnosed with any of the following conditions, you should inform your doctor, pharmacist, or nurse, as they may advise you to stop taking Aerinaze:
If you are scheduled to undergo surgery, your doctor may advise you to stop taking Aerinaze 24 hours before.
One of the active substances of Aerinaze, pseudoephedrine sulfate, has the potential for abuse and large doses of pseudoephedrine sulfate can be toxic. Continuous use can lead to taking more Aerinaze than the recommended dose to achieve the desired effect, increasing the risk of overdose. If treatment is suddenly interrupted, depression may occur.
Laboratory Tests
Stop taking Aerinaze at least 48 hours before undergoing skin tests, as antihistamines may affect the results of skin tests.
Athletes taking Aerinaze may test positive for doping.
Use in Children and Adolescents
Do not give this medicine to children under 12 years of age.
Other Medicines and Aerinaze
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines. This is especially important if you are taking:
Taking Aerinaze with Alcohol
Talk to your doctor, pharmacist, or nurse about whether you can drink alcohol while taking Aerinaze. It is not recommended to drink alcohol while taking Aerinaze.
Pregnancy, Breast-feeding, and Fertility
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Aerinaze is not recommended during pregnancy.
Pseudoephedrine sulfate, one of the components of Aerinaze, has been reported to decrease milk production in breast-feeding women. Both desloratadine and pseudoephedrine sulfate are excreted in breast milk. Aerinaze is not recommended during breast-feeding.
Fertility
No data are available on male and female fertility.
Driving and Using Machines
At the recommended dose, this medicine is not expected to affect your ability to drive or use machines. Although most people do not experience drowsiness, it is recommended not to engage in activities that require mental alertness, such as driving a car or operating machinery, until you have determined your own response to the medicine.
Follow exactly the administration instructions of this medicine given by your doctor, pharmacist, or nurse. If you are unsure, consult your doctor, pharmacist, or nurse again.
Adults and Adolescents from 12 Years of Age
The recommended dose is one tablet twice a day with a glass of water, with or without food.
This medicine is for oral use.
Swallow the tablet whole; do not crush, break, or chew it before swallowing.
Do not take more tablets than recommended in the leaflet. Do not take tablets more frequently than recommended.
Do not take this medicine for more than 10 consecutive days unless your doctor tells you to.
If You Take More Aerinaze Than You Should
If you take more Aerinaze than you should, inform your doctor, pharmacist, or nurse immediately.
If You Forget to Take Aerinaze
If you forget to take your dose on time, take it as soon as possible and then continue with your regular dosing schedule. Do not take a double dose to make up for forgotten doses.
If You Stop Taking Aerinaze
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects have been observed in studies:
Frequent: may affect up to 1 in 10 people
|
|
|
Uncommon: may affect up to 1 in 100 people
|
|
|
Rare: the following side effects have been reported during marketing of desloratadine and may affect up to 1 in 10,000 people
|
|
|
Frequency not known: frequency cannot be estimated from the available data
|
|
|
|
Severe skin reactions, which include signs and symptoms such as fever, skin redness, or many small bumps, have been reported with pseudoephedrine-containing medicines.
Reporting of Side Effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month shown.
Do not store above 30°C. Store the blisters in the outer carton to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Aerinaze
Appearance of the Product and Contents of the Pack
Aerinaze is a modified release, oval, two-layer tablet (blue and white), with “D12” engraved on the blue layer. Aerinaze tablets are presented in blisters of 2, 4, 7, 10, 14, or 20 tablets formed by a blister pack with an aluminum foil lid.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
Manufacturer:
SP Labo N.V.
Industriepark 30
B-2220 Heist-op-den-Berg
Belgium.
For further information on this medicine, contact the local representative of the Marketing Authorization Holder:
Belgium MSD Belgium BVBA/SPRL Tel: +32 (0)2 776 62 11 dpoc_belux@merck.com | Lithuania UAB Merck Sharp & Dohme Tel: + 370 5 278 02 47 msd_lietuva@merck.com |
Bulgaria Merck Sharp & Dohme Bulgaria EOOD Tel: +359 2 819 3737 info-msdbg@merck.com | Luxembourg MSD Belgium BVBA/SPRL Tel: +32 (0)2 776 62 11 dpoc_belux@merck.com |
Czech Republic Merck Sharp & Dohme, s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com | Hungary MSD Pharma Hungary Kft. Tel: +36 1 888-5300 hungary_msd@merck.com |
Denmark MSD Danmark ApS Tel: + 45 4482 4000 dkmail@merck.com | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Germany MSD SHARP & DOHME GMBH Tel: 0800 673 673 673 (+49 (0) 89 4561 2612) e-mail@msd.de | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Estonia Merck Sharp & Dohme OÜ Tel: + 372 6144 200 msdeesti@merck.com | Norway MSD (Norge) AS Tel: +47 32 20 73 00 msdnorge@msd.no |
Greece MSD Α.Φ.Β.Ε.Ε. Tel: +30 210 98 97 300 dpoc_greece@merck.com | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 msd-medizin@merck.com |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@merck.com | Poland MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com |
France MSD France Tel: + 33 (0)1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 214465700 inform_pt@merck.com |
Croatia Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 croatia_info@merck.com | Romania Merck Sharp & Dohme Romania S.R.L. Tel: + 40 21 529 2900 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@merck.com | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 5204 201 msd.slovenia@merck.com |
Iceland Vistor hf. Tel: + 354 535 70 00 | Slovak Republic Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com |
Italy MSD Italia S.r.l. Tel: +39 06 361911 medicalinformation.it@merck.com | Finland MSD Finland Oy Tel: + 358 (0)9 804 650 info@msd.fi |
Cyprus Merck Sharp & Dohme Cyprus Limited. Tel: 800 00 673 (+357 22866700) cyprus_info@merck.com | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@merck.com |
Latvia SIA Merck Sharp & Dohme Latvija Tel: + 371 67364224 msd_lv@merck.com | United Kingdom Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com |
Date of Last Revision of this Leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/.